NEW YORK, August 1, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding BP plc (NYSE: BP), Schlumberger Limited (NYSE: SLB), Eastman Chemical Company (NYSE: EMN), Monsanto Company (NYSE: MON) and E I Du Pont De Nemours And Co. (NYSE: DD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5353-100free.
--
BP plc Research Reports
On July 29, 2014, BP plc (BP) released its Q2 2014 and H1 2014 financial results. The Company reported Q2 2014 total revenues and other income of $95.8 billion, flat YoY. The Company's Q2 2014 profit attributable to BP shareholders came in at $3.4 billion or 18.15 cents per diluted share, compared to $2.0 billion or 10.68 cents per diluted share in Q2 2013. The Company reported H1 2014 total revenue and other income of $188.8 billion, down 7.0% YoY. The Company's H1 2014 profit attributable to BP shareholders came in at $6.9 billion or 37.11 cents per diluted share, compared to profit of $18.9 billion or 98.53 cents per diluted share in H1 2013. The Company also announced a quarterly dividend of 9.75 cents per ordinary share for Q2 2014, up 8.3% YoY. The full research reports on BP are available to download free of charge at:
http://www.analystsreview.com/Aug-01-2014/BP/report.pdf
--
Schlumberger Limited Research Reports
On July 17, 2014, Schlumberger Limited (Schlumberger) posted Q2 2014 revenue of $12.1 billion, up 7.8% YoY, surpassing Zacks consensus revenue estimate of $11.9 billion. The Company's Q2 2014 Net income came in at $1.6 billion or $1.21 per diluted share (Vs. Zacks consensus estimate of $1.35 per share), compared to net income of $2.1 billion or $1.57 per diluted share in Q2 2013. The Company reported H1 2014 revenue of $23.3 billion, up 7.1% YoY. The Company's H1 2014 Net income came in at $3.2 billion or $2.42 per diluted share, compared to net income of $3.4 billion or $2.51 per diluted share in H1 2013. As on June 30, 2014, the Company's cash and short-term investments were $6.7 billion, compared to that of $8.4 billion on December 31, 2013. The full research reports on Schlumberger are available to download free of charge at:
http://www.analystsreview.com/Aug-01-2014/SLB/report.pdf
--
Eastman Chemical Company Research Reports
On July 28, 2014, Eastman Chemical Company (Eastman) released its Q2 2014 and H1 2014 financial results. The Company reported Q2 2014 sales of $2.46 billion, up 0.8% YoY, missing Zacks Consensus Estimate of $2.52 billion. During the quarter, the Company's operating earnings improved 1.9% YoY to $436 million. The Company's Q2 2014 net earnings attributable to Eastman stockholders came in at $292 million or $1.93 per diluted share, compared to $264 million or $1.69 per diluted share in Q2 2013. Earnings from continuing operations, excluding one-time items, were $1.92 per share during the quarter, topping the Zacks Consensus Estimate of $1.84. The Company reported H1 2014 sales of $4.8 billion, up 0.4% YoY. The Company's H1 2014 net earnings attributable to Eastman stockholders came in at $525 million or $3.45 per diluted share, compared to $511 million or $3.26 per diluted share in H1 2013. Mark Costa, Chairman and CEO, Eastman, stated that the Company is expected to post full-year 2014 EPS in the range of $6.70 - $7.00. The full research reports on Eastman are available to download free of charge at:
http://www.analystsreview.com/Aug-01-2014/EMN/report.pdf
--
Monsanto Company Research Reports
On July 29, 2014, Monsanto Company (Monsanto) along with its subsidiary The Climate Corporation (Climate) joined a roundtable of experts at the White House to share its ideas and research approaches to help the world's farmers manage and adapt to the impact of climate change on the global food supply. During the roundtable discussion, which focused on the White House Climate Data Initiative, many researchers and leaders from the public and private sectors shared their updates on use of data insights and analysis to better understand climate issues and develop new solutions to address them. Further, the Company representatives also shared updates on collaborative efforts that have upgraded the use of models - data-driven analyses of how plants react to extreme weather conditions, water availability and changes in weather. The full research reports on Monsanto are available to download free of charge at:
http://www.analystsreview.com/Aug-01-2014/MON/report.pdf
--
E I Du Pont De Nemours And Co. Research Reports
On July 19, 2014, E I Du Pont De Nemours And Co.'s (Du Pont) Chairman and CEO, Ellen Kullman issued a statement on demise of Stephanie Kwolek, a DuPont Scientist. Ellen Kullman said, "We are all saddened at the passing of DuPont scientist Stephanie Kwolek, a creative and determined chemist and a true pioneer for women in science. Her synthesis of the first liquid crystal polymer and the invention of DuPont' Kevlar® highlighted a distinguished career. In 1996, she became the third DuPont scientist to win a National Medal of Technology or of Science. She leaves a wonderful legacy of thousands of lives saved and countless injuries prevented by products made possible by her discovery." The full research reports on Du Pont are available to download free of charge at:
http://www.analystsreview.com/Aug-01-2014/DD/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
